Status:
COMPLETED
The Vienna Prograf and Endothelial Progenitor Cell Study
Lead Sponsor:
Medical University of Vienna
Conditions:
End Stage Renal Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The aim of the study is to determine if the conversion from the immunosuppressive agent cyclosporine to tacrolimus contributes to an improvement of the cardiovascular risk factors, better kidney funct...
Detailed Description
In addition to hypertension, diabetes, hyperlipidemia and smoking, as well as other non-traditional risk factors such as elevated C-reactive protein, homocysteine, Lp(a), or reduced renal function, de...
Eligibility Criteria
Inclusion
- Patient is recipient of a deceased or living donor renal transplant (including retransplants) Patient is 18 years or age or older at the time of transplantation. Patient is at least 6 months post-transplant. Patient is on a cyclosporine-based immunosuppression regimen o combination with/without mycophenolate mofetil and/or steroids at study entry.
- Patient has a functioning renal allograft and estimated GFR≥39 mL/min/1.73m2 within four weeks prior to study entry.
- Patient has a stable graft function without biopsy proven acute rejection episode within 3 months prior to study entry.
- Patient has not experienced a cardiovascular event. Patient has fully been informed and has given written informed consent according to the International Conference on Harmonization, Good Clinical Practice.
- Females are not pregnant and agree to practice effective birth control while receiving immunosuppressant medication.
- Patient has indications for conversion at the investigators discretion or is suffering from cyclosporine associated side effects like hypertension, hyperlipidemia or cosmetic side effects.
Exclusion
- Patient is recipient of a solid organ transplant other than the kidney. Patient has recurrence of primary renal disease, or de novo renal disease. Patient is pregnant or lactating. Patient had known or suspected malignancy (except for treated squamous and basal cell skin cancers) \<5 years before study entry or a history of post-transplant lymphoproliferative disease (PTLD).
- Patient has known hypersensitivity to tacrolimus, or any of the recipients of the drug.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
148 Patients enrolled
Trial Details
Trial ID
NCT00182559
Start Date
April 1 2004
End Date
May 1 2009
Last Update
February 5 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090